Clinical trials: Overweight, Obesity
Healthy, Obese
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on…
- Trial name
- NCT05841238
- Testing
- LY3502970
- Where
- 3 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
- Trial name
- FALCON (NCT06854952)
- Testing
- TERN-601
- Where
- 17 sites in United States
- Volunteers
- 167 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Overweight, Obesity
Dietary Supplementation on Fat Oxidation
The purpose of this pilot study is to evaluate the effects of 4 weeks of daily consumption of encapsulated N-trans-caffeoyl tyramine (NCT) and N-trans-feruloyl tyramine (NFT) at a dose of 120 mg/d on measures of fat oxidation in…
- Trial name
- NCT06548048
- Testing
- Dietary supplement containing plant derived phenolics, Microcrystaline cellulose
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brightseed
Obesity, Morbid
LAP-BAND AP Early Experience Trial (APEX)
The purpose of this study is to evaluate the LAP-BAND AP System in severely obese patients.
- Trial name
- NCT00501085
- Testing
- LAP-BAND AP Adjustable Gastric Banding System
- Where
- United States
- Volunteers
- 521 people
- Sponsor
- Apollo Endosurgery, Inc.
Obesity
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
- Trial name
- NCT00396448
- Testing
- CP-945,598 Treatment B, CP-945,598 Treatment A
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 1,253 people
- Sponsor
- Pfizer
Obesity
A Phase 1b Study to Evaluate the Safety of XEN-101
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
- Trial name
- NCT06417697
- Testing
- XEN-101
- Where
- Australia
- Volunteers
- 33 people
- Sponsor
- Xeno Biosciences
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
- Trial name
- NCT00567255
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, Ancillary therapy
- Where
- 36 sites in United States
- Volunteers
- 1,496 people
- Sponsor
- Orexigen Therapeutics, Inc
Metabolism and Nutrition Disorder, Obesity
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
This trial will be conducted in the United States of America (USA). The aim of this clinical trial is to investigate whether NNC 0070-0002-0349 is safe and well tolerated.
- Trial name
- NCT00728455
- Testing
- NNC 0070-0002-0349
- Sponsor
- Novo Nordisk A/S
Morbid Obesity
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
The pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs.
- Trial name
- NCT05486325
- Testing
- Endolumik Gastric Calibration Tube (EGCT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Endolumik, Inc
Type2 Diabetes Mellitus, Obesity
Neujia Anastomosis for Treatment of Obesity and Type II Diabetes
This prospective, multicenter, open label, single arm study will enroll subjects presenting with obesity and inadequately controlled type II diabetes (T2DM).
- Trial name
- NEUJIA 1A (NCT03675074)
- Testing
- Neujia
- Sponsor
- Neurotronic, Inc.
Metabolism and Nutrition Disorder, Obesity
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.
- Trial name
- NCT01789086
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes Mellitus
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899.
- Trial name
- NCT03376802
- Testing
- SAR425899
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Overweight, Diabetes
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
- Conditions
- Overweight, Diabetes, PreDiabetes, Obesity
- Trial name
- LIGHT-UP (NCT03058029)
- Testing
- Gelesis200
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Gelesis, Inc.
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.